Invokamet combines Invokana (canagliflozin), a sodium glucose co-transporter 2 (SGLT2) inhibitor, with metformin, a biguanide antidiabetic. Canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Six Phase 3 clinical trials evaluated Invokana in combination with metformin vs. metformin alone or to metformin plus another diabetes therapy in 4,732 patients with type 2 diabetes. Results of the Phase 3 studies showed that the co-administration of Invokana and metformin lowered glucose and was associated with significant reductions in body weight and systolic blood pressure.
Invokamet will be available in 50mg/500mg, 50mg/1000mg, 150mg/500mg, and 150mg/1000mg tablets in 60-count bottles.
For more information call (877) 468-6526 or visit Invokamet.com.